With the clinical introduction of several novel, ultrapotent PARP inhibitors (with ovarian and breast cancer being their approved indications), the concept that PARP inhibitors may have potential clinical utility in various non-oncological diseases, including ALI, through drug repurposing has received renewed justification [9,10,11,12,13]. Here, PARP1 is linked to breast cancer.